The Life Sciences team advised Exosome Diagnostics on its definitive agreement to be acquired by Bio-Techne Corporation for $250 million in cash plus contingent consideration of up to $325 million due upon the achievement of certain future milestones. The transaction is expected to close by early August 2018.
Exosome Diagnostics develops and sells diagnostics that test for exosomes, which are nanoparticles found in biological fluids. Currently Exosome Diagnostics markets a urine-based test, ExoDx® Prostate(IntelliScore) (EPI), to assist physicians in determining the need for a prostate biopsy in patients with an ambiguous PSA test result. Exosome Diagnostics is supported by a top-tier investor syndicate including Forbion Capital Partners, Tiger Management and NGN Capital Partners.
For additional details on the acquisition, please read the press release.